###### Strengths and limitations of this study

-   The first systematic review of interventions for methamphetamine (MA) use and associated mental health outcomes.

-   This systematic review will reduce and protect against risk of bias.

-   If a meta-analysis is possible, this can detect small but clinically relevant effects of interventions to reduce MA use and improve MH outcomes.

-   Most trials have been conducted in Western countries, so generalisability of findings to other contexts is unknown.

-   If a meta-analysis is appropriate, conducting this form of analysis can mean that an assumption is made about the methodology of interventions as being consistent across studies.

Introduction {#s1}
============

Rationale {#s1a}
---------

Methamphetamine (MA) is a psychostimulant that when used regularly is associated with harms such as injecting and sexual risk-taking behaviour, symptoms of mental ill health (eg, psychosis, aggression, depression and/or anxiety), psychomotor, social and cognitive impairment, criminal activity and sometimes death caused by overdose.[@R1] MA use can be considered problematic if an individual continues the use of the drug despite experiencing significant harms.[@R8] Increased production and availability of the drug has influenced regular use, consequently increasing drug-related harms.[@R7]

Substance use accounts for an increasing proportion of the global burden of disease.[@R9] Amphetamine-type stimulants have become the most prevalent type of psychostimulants used in the world, and it is estimated that there are 24 million users worldwide.[@R10] In South Asia and the Middle East, MA is becoming increasingly popular, and use is already well established in the USA, Australia, China, Mexico and Thailand.[@R10] Due to the drug's psychological and medical impact, the detrimental effects can be seen in entire communities, whole populations and individual users.[@R10]

The disease burden in Australia attributable to MA is of international relevance as Australia has reputable data for mortality rates, and the rates of illicit drug use are similar to those in other high-income countries.[@R11] In recent years, a more potent form of MA (crystal) has increased in popularity across the globe and particularly in Asia and Australia.[@R12] Smoking crystal MA is the most popular form of use in Australia, followed by injection.[@R10] Although MA was used by only 2% of Australian adults in the 12 months to 2013,[@R12] the use of crystal MA had doubled since 2010 from 22% to 50%. In addition, the proportion of people using daily or weekly increased from 12% to 25% over the same period.[@R12]

The shift to crystal MA use in Australia has seen mental health problems associated with this form of the drug substantially worsen. From 2009 to 2014, the annual total number of mental health presentations, overdose and drug and alcohol presentations at NSW public hospital emergency departments related to MA use increased more than sevenfold, from 394 to 296.[@R13] This rise in mental health presentations associated with crystal MA use has led to increased interest in mental health treatment outcomes following treatment for MA use.

Psychostimulants are a unique group of substances because they are more likely to induce psychosis than other illicit drugs.[@R14] Although vulnerability to psychotic symptoms differs among people who use MA, these symptoms are more apparent in people who use MA on a regular basis.[@R14] In addition, depression, anxiety, suicidal ideation, dysphoria and cognitive deficits have been commonly reported to co-occur in people using MA.[@R1] McKetin *et al* [@R17] reported that a quarter of people using MA in their cross-sectional study experienced severe disability in their psychological functioning. Glasner-Edwards *et al* [@R18] identified that people who experience depressive symptoms and use MA may have a poorer prognosis for both conditions and may experience worse treatment outcomes. Furthermore, Newton *et al* [@R19] suggested that depressive symptoms may contribute to negative reinforcement and more frequent use of MA, consequently impacting on psychological treatment outcomes. In summary, it appears that MA use is associated with an array of psychological difficulties that may affect one's response to treatment.[@R20]

Psychological treatment, incorporating elements such as psychotherapy, psychoeducation and relapse prevention are major treatments for MA use that focus on abstinence and reducing symptoms of mental ill health. Treatment retention can be difficult for MA users in psychological treatment.[@R21] Pharmacotherapies have been used in conjunction with the aim of improving treatment engagement and retention;[@R21] however, research on the efficacy of pharmacotherapies to date has produced inconsistent results.[@R22] There is no evidence to suggest that agonist drug treatments can reduce psychological distress associated with MA use.[@R23] In a review conducted by Elkashef *et al*,[@R25] pharmacotherapies such as bupropion and sertraline did not increase abstinence from MA in groups who received this drug compared with controls.[@R26] The evidence base for pharmacological approaches for MA use is limited, with conflicting evidence for medication approaches, for withdrawal, maintenance or relapse prevention treatment.[@R27]

In line with the psychological and public health implications of MA use, there has been a considerable amount of research on psychological treatments for treating MA use and withdrawal.[@R28] Thus, psychological treatment is the primary treatment available for people who use MA, and also appears to have the most solid evidence base.[@R29] Contingency management (CM) has been shown to be an efficacious psychological treatment for people who use MA[@R31] and has increased MA abstinence and decreased MA-related risk behaviour.[@R5] Certain psychological interventions, such as cognitive behavioural therapy (CBT) (including the Matrix Model), and approaches, such as Motivational Interviewing,[@R27] have been effective in reducing MA use and reducing depressive symptoms in people who use MA.[@R29] These interventions have also been associated with positive mental health outcomes, such as improved well-being, following treatment in people who use MA.[@R34] However, it remains unclear as to what psychological interventions provide the most solid evidence base for reducing MA use and symptoms of mental ill health. As mental health symptoms are increasingly common and increasing in severity among people who use MA, there is a requirement for research on the efficacy of psychological interventions for MA use and mental health symptomatology.

Why is it important to do this review? {#s1b}
--------------------------------------

Further clarity regarding evidence for the efficacy of psychological treatments for MA use and co-occurring mental health symptoms or conditions is necessary. A Cochrane review conducted by Minozzi *et al* [@R35] researched psychological interventions for psychostimulant use and covered a broad range of psychostimulants, including amphetamine-type stimulants, MDMA and cocaine. However, that review did not focus on MA and mental health outcomes, and only included two studies measuring depression and MA use. A review by Shoptaw *et al* [@R36] focused on treatment for amphetamine withdrawal, incorporating psychological and pharmacological treatment, and primarily focused on the withdrawal syndrome when using amphetamines. Another review by Shoptaw *et al* [@R37] focused on pharmacological treatment for amphetamines and psychosis. Cochrane reviews have assessed treatment for MA withdrawal and found no effective medication approaches.[@R27]

Hellem *et al* [@R4] conducted a review on MA and coexisting depressive symptoms, reviewing nine studies incorporating psychological intervention only; psychological combined with pharmacological interventions; and pharmacological only, and found no research supporting one single treatment approach over others on either MA or depression outcomes. Overall, it appears that psychological therapies remain the most effective treatment option for MA use, and that pharmacotherapies may be used as an adjunct.[@R21] As it is difficult to maintain enduring behaviour changes in people who experience problems with drug use,[@R29] the longevity of treatment effects relating to long-term abstinence and a range of mental health symptoms or conditions should be further assessed.[@R38]

Cochrane reviews conducted thus far have not focused on psychological treatment for MA and co-occurring symptoms of mental ill health.[@R35] The present review will focus on studies which have measured MA use and mental health symptomatology or diagnoses at baseline and post-treatment. It will report on MA use outcomes, MA use and mental health symptom outcomes, and MA use and coexisting mental disorders. A review of this kind will contribute to the literature by highlighting psychological interventions that can reduce the global public health burden of disease in terms of MA use and mental health outcomes.[@R41] Thus, this review will assess the effectiveness of psychological treatments in reducing MA use and associated symptoms of mental ill health.[@R41] Results will assist public health and clinical use of treatment for coexisting MA use and mental health symptoms or conditions.[@R42] This systematic review represents an important step in summarising the available evidence for psychological treatment for MA use and will allow for identification of areas for future research.

Objectives {#s1c}
----------

Employing studies of psychological treatment of MA use which measure MA use and mental health symptoms or mental disorders at baseline and post-treatment, the aims of this review are toexamine the effectiveness of psychological treatments in reducing MA use and/or increasing abstinence rates among people who use MA;examine the effectiveness of psychological treatments for coexisting mental health symptoms or mental disorders among people who use MA;conduct secondary analyses examining other outcomes following psychological treatment (bloodborne virus (BBV) risk behaviour, other substance use, treatment engagement, retention, physical activity, quality of life, global assessment of functioning) and potential mediators;identify future research directions.

Review questions {#s1d}
----------------

For adults using MA:Does psychological treatment change (reduce/increase) symptoms of mental ill health or coexisting mental disorders?What psychological treatments are effective in reducing MA use and/or increasing abstinence rates?What psychological treatments are effective in changing (reducing/increasing) symptoms of mental ill health or coexisting mental disorders?Is the effectiveness of psychological treatment for MA use influenced by treatment engagement (quantity, frequency and/or duration of therapy attendance)?

Methods and analysis {#s2}
====================

A systematic review will be conducted using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.[@R43]

Eligibility criteria {#s2a}
--------------------

### Types of studies {#s2a1}

This systematic review is focused on the efficacy of psychological interventions for reducing MA use. Studies included will report (1) MA use and (2) mental health symptoms and/or disorders at baseline and post-treatment. Controlled trials such as randomised controlled trials (RCTs, cluster and parallel design) will be eligible. Case controls, crossover trials, one-arm trials, non-randomised trials, cross-sectional studies and cohort studies will be excluded.

### Types of participants {#s2a2}

Participants included in the review will be adults (over 18 years), using MA alone or in combination with other substances (polydrug use). Participants may be in an inpatient unit (drug and alcohol rehabilitation or hospital setting), residing in the community, engaging in psychotherapy or inmates in a prison setting.

### Types of interventions {#s2a3}

Psychological interventions of interest include behaviour therapy, CM, CBT, the community reinforcement approach, acceptance and commitment therapy, dialectical behaviour therapy, motivational interviewing, psychotherapy, group therapy, mutual aid (narcotics anonymous/SMART recovery) and residential treatment. Web-based, telephone and smartphone delivered interventions will also be included. Interventions delivered in any setting will be included (eg, private practice, hospital, rehabilitation and residential treatment centre). Psychological interventions must include one or more psychological strategies designed to modify behaviour.

### Types of comparison conditions {#s2a4}

Interventions may be compared with active controls (eg, psychological interventions and 12-step programmes), treatment as usual (TAU) and/or inactive controls (eg, wait-list control or standard care). Interventions can be of any duration, delivery, frequency and intensity.

Types of outcome measures {#s2b}
-------------------------

### Primary outcomes {#s2b1}

1.  Any outcome measure reporting change (reduction/increase) or abstinence in MA use following psychological treatment for MA use.

2.  Any outcome measure reporting change (reduction/increase) in mental health symptoms or diagnoses following psychological treatment for MA use.

### Secondary outcomes {#s2b2}

1.  Change in other drug use following psychological treatment. Reduction/increase or abstinence in drug use (tobacco, amphetamine-type stimulants, alcohol, cannabis, cocaine, opioids, tranquillizers or polydrug use) following treatment.

2.  Treatment engagement and retention in psychological treatment for MA use.

3.  BBV risk reduction (injecting drugs/sexual risk behaviour) following psychological treatment for MA use.

4.  Change in physical health following treatment.

5.  Change in aspects of quality of life following treatment.

6.  Difference in levels of functioning pretreatment and post-treatment (global assessment of functioning or social functioning).

Outcomes reflect any time frame (eg, short-term and long-term) and can be rated by clients or clinicians, in the form of an assessment by objective or subjective measures (eg, questionnaire, monitoring form, urine and blood).

Information sources {#s2c}
-------------------

### Search strategy {#s2c1}

The search strategy will follow the Cochrane Handbook for Systematic Reviews of Interventions. In June 2016, we consulted with a qualified librarian and identified relevant scientific electronic databases (MEDLINE, EMBASE, CINAHL, PsychINFO, Scopus). Registration databases will also be searched (Cochrane Central Register of Clinical Trials, US government website of clinic trials and WHO International Clinical Trials Registry).

Search terms were developed from existing reviews to cover psychological interventions[@R2] (eg, CBT and CM) and MA (see online [supplementary appendix A](#SP1){ref-type="supplementary-material"}). The MEDLINE expert search for RCTs will be used to identify RCTs. Subject headings, titles, keywords and abstracts specific to each of the identified databases will be recognised and subject headings will be exploded to allow narrower terms to be included where possible. Publications will be limited to human studies. No limits will be placed on publication year. Publications must be available in English to be included, but any non-English language publications that are eligible on the basis of a translated abstract will be noted. Reference lists of publications and extra studies not identified by the original search will be hand searched to identify any further publications. All publications will be organised using Endnote. Prior to final analyses, searches will be rerun and further studies will be retrieved for inclusion.
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###### Supplementary Appendix 1

Classification of studies {#s2d}
-------------------------

Titles and abstracts will be identified by AS and a second reviewer using the following three-step process.

### Step 1: identification of studies for exclusion {#s2d1}

Step 1 will involve identifying studies for exclusion. Titles and abstracts will be reviewed and excluded if articles are (1) not peer-reviewed journal articles, (2) duplicates, (3) do not use a controlled design, (4) do not include a psychological intervention or (5) do not include relevant behavioural change outcome measures associated with MA use or mental health outcomes.

### Step 2: classification of studies {#s2d2}

Step 2 will involve classification of studies, in which full text and/or abstracts of any remaining studies will be examined to identify studies to be evaluated, including reviews (summaries, descriptive, critical and/or systematic reviews) and controlled studies.

### Step 3: cross-checking {#s2d3}

Step 3 will involve cross-checking publications found in previous steps to check for eligibility and reclassified if necessary. In case of disagreement between reviewers, the final classification will be made by consensus, with the involvement of a third reviewer (ALB). Articles excluded in Step 1 will not be cross-checked because they will not be relevant. Studies identified in Step 2 will be retained for further examination.

Data extraction from evaluation studies {#s2e}
---------------------------------------

Data extraction will be performed by AS and a second reviewer. Before using the extraction form, it will be piloted on several studies and adapted as needed. When duplicate reports of the same study are identified (eg, conference abstracts or associated journal articles), data from each report will be extracted independently and then combined across multiple data collection forms. In accordance with Cochrane guidelines, methodological critique and assessment of risk of bias will be conducted individually by two raters and judgements reached by consensus. If a disagreement occurs, a third independent rater will establish final ratings made via consensus. The occurrence and resolution of any disagreements will be recorded to allow for the assessment of reliability of coding. If there are not enough details of trials reported, then authors of studies will be contacted.

To ensure functionality, extraction forms will be pretested in 10% of the identified articles. The Cochrane Handbook for Systematic Reviews[@R45] will be used to guide data extraction. Data extraction will include:Participant information: n values at each stage of the study (at baseline and follow-up, and include reasons for non-participation), eligibility criteria, treatment setting, descriptive data, diagnostic criteria and treatment history.Methods of each study: design and setting (country), methodological limitations reported and observed (eg, recruitment allocation and data collection methods, blinding, comparability of groups at baseline, appropriateness of analysis).Type of interventions: duration of treatment (number of sessions), number of groups, type of sessions (group/individual), method of delivery and description of control intervention(s).Primary and secondary outcomes: percentage of treatment sessions attended, data collection sources/methods, process measures/mediators/mechanisms, economic outcomes, satisfaction-related outcomes and follow-up period.Results of studies: primary (change in MA use and mental health outcomes) and secondary outcomes (BBV risk behaviour, other substance use, treatment engagement, retention, physical activity, quality of life and global assessment of functioning).

Methodological critique of evaluation research {#s2f}
----------------------------------------------

Review authors will perform risk of bias assessments and methodological critique independently (AS and second reviewer), and a third person will resolve discrepancies (AB). If disagreement occurs, final ratings will be made via consensus, following discussion with coauthors.[@R46] The 'Cochrane Collaboration's Risk of Bias' tool will be used to measure risk of bias[@R45] with items judged as low, high or unclear risk. A 'high' or 'unclear' risk of bias will be deemed by allocation concealment and selection bias, as these factors have been suggested to be sources of bias from previous research.[@R45]

Grading the strength of evidence {#s2g}
--------------------------------

The overall quality of evidence on outcomes will be presented using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation)[@R45] approach. This involves consideration of within study risk of bias, heterogeneity, directness of evidence, precision of effect estimates and risk of publication bias. The overall quality of evidence will be rated at four levels: high, moderate, low and very low.

Measures of treatment effect {#s2h}
----------------------------

A quantitative synthesis of the outcomes from the included studies will be reported, using a meta-analysis if possible. If a meta-analysis or quantitative synthesis is not possible for some studies (due to lack of comparable interventions or outcome measures), a narrative synthesis of the findings will be used to report outcomes. This synthesis will be formatted around intervention content and type, population features and outcomes. The context of treatment (eg, psychological versus active control) and the type of outcomes will be described. Where possible, 'summary of findings' (SOF) tables will be created for each comparison (eg, psychological intervention versus TAU). These tables will provide key information regarding evidence quality, a summary of available data on outcome variables and the degree of the effect of interventions.

Dichotomous outcome measures {#s2i}
----------------------------

Risk ratios (RR) will be used to measure dichotomous outcome measures,[@R47] where a 95% CI will be provided for the primary outcome of each trial.

Continuous outcome measures {#s2j}
---------------------------

Continuous outcome measures will be measured by Cohen's *d* to calculate effect sizes. A small effect size will be considered as 0.2--0.49, a moderate effect size is 0.5--0.79 and a large effect size is greater than 0.8.[@R48] If sample sizes are small, Hedge's *g* will be used in place of *d.*

Ethics and dissemination {#s2k}
------------------------

As data have already been published and analysis is secondary, no ethics approval is required. Findings of this systematic review will be presented for peer review in an appropriate journal. Findings will be presented to researchers and clinicians at suitable conferences.

Amendments {#s2l}
----------

If the protocol needs to be amended, the date of each amendment, the change and the rationale will be described in this section. The search strategy was amended on the 26th of July 2017 following consultation with a research librarian. This was following revision of the previous search strategy created in 2016, to ensure clarity and to make the search more robust in nature. The new search ensures that both the relevant MESH headings as well as keyword searches are used. Additionally, correct truncation was applied, and adjacency searches standardised across each of the searches.
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